CHEK2 and hematopoietic and lymphoid cell neoplasm: Reports of increased risk of lymphoid and hematologic malignant neoplasms (especially CLL) in individuals with heterozygous CHEK2 variants date from 200621,31,32 but were conflicting and/or based on highly ascertained families.